| | | | | | | RegenMD | | | | | | | | | | | | | | | | Single cell transcriptional profiling reveals heterogeneity of human induced pluripotent stem cells. J Clin Invest. 2011 Mar 1;121(3):1217-21 Authors: Narsinh KH, Sun N, Sanchez-Freire V, Lee AS, Almeida P, Hu S, Jan T, Wilson KD, Leong D, Rosenberg J, Yao M, Robbins RC, Wu JC Human induced pluripotent stem cells (hiPSCs) and human embryonic stem cells (hESCs) are promising candidate cell sources for regenerative medicine. However, despite the common ability of hiPSCs and hESCs to differentiate into all 3 germ layers, their functional equivalence at the single cell level remains to be demonstrated. Moreover, single cell heterogeneity amongst stem cell populations may underlie important cell fate decisions. Here, we used single cell analysis to resolve the gene expression profiles of 362 hiPSCs and hESCs for an array of 42 genes that characterize the pluripotent and differentiated states. Comparison between single hESCs and single hiPSCs revealed markedly more heterogeneity in gene expression levels in the hiPSCs, suggesting that hiPSCs occupy an alternate, less stable pluripotent state. hiPSCs also displayed slower growth kinetics and impaired directed differentiation as compared with hESCs. Our results suggest that caution should be exercised before assuming that hiPSCs occupy a pluripotent state equivalent to that of hESCs, particularly when producing differentiated cells for regenerative medicine aims. PMID: 21317531 [PubMed - indexed for MEDLINE] | | | | | | | | | | | | | | | | | | | | | "We're trying to come up with ways of self-assembling little tissue units," says Ali Khademhosseini, an associate professor at Brigham and Women's Hospital at Harvard Medical School and a specialist in tissue engineering who is collaborating with ... See all stories on this topic » | Next Big Future | | | | | | | | | | | | | | | | | | | | | | By TRAVIS FAIN | Winston-Salem Journal The Wake Forest Institute for Regenerative Medicine in Winston-Salem would take a multimillion-dollar hit under the state budget moving forward in the NC House of Representatives. Instead of getting $10 million a ... See all stories on this topic » | | | | | | | | | | | | | | | | | | | | | The new doctoral program in stem cell biology and regenerative medicine is also the first interdisciplinary doctoral program created by the School of Medicine in recent years. School officials say the fact that the university is taking the rare step of ... See all stories on this topic » | Scope (blog) | | | | | | | | | | | | | | | | | | | | | | The university's Center for Stem Cell Biology and Regenerative Medicine will work with Paragon Bioservices Inc., based in the university's BioPark, to offer stem cell services, such as the production and storage of various types of stem cells. ... See all stories on this topic » | | | | | | | | | | | | | | | | | | | | | ... MI • Jeremy N. Rich, MD, chairman, Department of Stem Cell Biology and Regenerative Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, OH • Evan Y. Snyder, MD, PhD, professor, Sanford-Burnham Medical Research Institute; director, ... See all stories on this topic » | | | | | | | | | | | | | | | | | | | | | The six inductees are: Argentina-born Dr. Albert Aguayo, who retired last year from McGill University in Montreal, initiated a rebirth of regenerative medicine by demonstrating that nerve fibres are capable of regeneration. Aguayo and his team were the ... See all stories on this topic » | | | | | | | | | | | | | | | | | | | | | What's the News: As a European court looks poised to ban the patenting of technologies using human embryonic stem cells (hESCs), a group of prominent scientists has issued a warning: regenerative medicine is never going to leave the lab if no one can ... See all stories on this topic » | Discover Magazine (blog) | | | | | | | | | | | | | | | | | | | | | | BALTIMORE, April 28, 2011 /PRNewswire/ -- UMB's Center for Stem Cell Biology and Regenerative Medicine and Paragon Bioservices, Inc., a contract research and GMP manufacturing organization with its headquarters at the University of Maryland BioPark, ... See all stories on this topic » | | | | | | | | | | | | | | | | | | | | | Non-GAAP adjusted earnings per share for our core Life Science Research Tools business ("LSRT") for the first quarter of 2011 was $0.08 and for our Regenerative Medicine business ("RMD") was a $0.01 per diluted share loss. These results were in line ... See all stories on this topic » | | | | | | | | | | | | | |
No comments:
Post a Comment